Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma
Status:
Recruiting
Trial end date:
2020-09-30
Target enrollment:
Participant gender:
Summary
This early phase I pilot trial studies how well patient-derived xenografts work in
personalizing treatment for patients with mantle cell lymphoma that has come back (relapsed)
or that isn't responding to treatment (refractory). Xenograft models involve taking a piece
of tissue from a tumor that was previously collected and putting that tissue inside of a
mouse in the laboratory. This allows the tumor to grow in the mouse so that researchers can
test the effects of certain drugs. If the drugs have an effect on the tumor(s) in the mice,
patients may receive that treatment for mantle cell lymphoma.
Phase:
Early Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Cancer Prevention Research Institute of Texas National Cancer Institute (NCI)